A Global Voice on Hangover Science: Dr. Joris Verster Publishes New Paper on Alcohol, Inflammation, and Health

Category 1 (1)

SJP-001 | Metabolic Recovery | Healthspan & Longevity

January 10 2025 Scientific Paper

Sen-Jam Pharmaceutical is proud to celebrate the recent publication of an insightful new paper by Dr. Joris C. Verster, one of our esteemed scientific advisors and a world-renowned expert in alcohol hangover research. The paper, titled “Alcohol Hangover: Time for a Paradigm Shift,” was just released in the Global Journal of Addiction & Rehabilitation Medicine, and it calls for a fundamental rethinking of how society—and science—addresses the impact of hangovers on public health.

In this powerful editorial, Dr. Verster argues that the traditional perception of hangovers as merely a nuisance overlooks their real-world consequences: impaired cognitive performance, reduced workplace productivity, and increased risk of accidents. He emphasizes the biological underpinnings of hangovers, particularly the inflammatory response triggered by alcohol consumption—an area where Sen-Jam’s own research and drug development efforts are deeply focused. Dr. Verster’s call to action for science, regulators, and the public to take hangovers more seriously resonates strongly with our mission to transform how we treat everyday inflammation-driven conditions.

 

Dr. Verster brings tremendous depth and credibility to this conversation. He is the founder of the Alcohol Hangover Research Group (AHRG) and a leading academic at Utrecht University and Leiden University in the Netherlands, with over 200 peer-reviewed publications. His commitment to rigorous, evidence-based research continues to advance global understanding of how lifestyle choices intersect with inflammation and health—making him an invaluable member of the Sen-Jam advisory team.

🧠 Read the full paper here: Alcohol Hangover: Time for a Paradigm Shift

📣 As we pioneer the first FDA-approved therapeutic for hangover prevention with SJP-001, we’re proud to have Dr. Verster helping lead the charge.

LINK TO THIS PAPER: https://juniperpublishers.com/gjarm/pdf/GJARM.MS.ID.555721.pdf

Recent Posts
Mask Group (20)

Patent Milestone and Stability Data Strengthen Licensing Value of SJP-002C

One year ago, we filed a provisional patent application for our Upper Respiratory Infection Therapeutic – SJP-002C, covering the novel manufacturing process for our dual-acting oral therapy…
Mask Group (17)

Sen-Jam Pharmaceutical Announces Planned AI Initiative for Molecule Repurposing

HUNTINGTON, N.Y., Jan. 10, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical (“Sen-Jam”), a pioneer in innovative inflammatory care, today announced a planned new initiative for use of leading-edge AI tools…
Encouragement Original 534082 Scaled 1 1 (1)

Sen-Jam Pharmaceutical Announces Ethics Approval in Australia for SJP-001 Clinic...

HUNTINGTON, N.Y., Jan. 14, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a leader in developing innovative solutions to address inflammation at its root cause, proudly announces that its flagship asset, SJP-001…

Media Inquiry